ADMA Biologics: A Deep Value Play or a Value Trap? DCF and P/E Analysis Point to Significant Undervaluation
Shares of ADMA Biologics (NASDAQ: ADMA) are trading near $16.49, presenting a stark contrast to valuation models. A detailed analysis using Discounted Cash Flow and a proprietary Fair P/E ratio suggests the biopharma stock may be deeply undervalued, despite recent mixed trading momentum.